IDH1 and IDH2 Mutations in — Glioma, AML and Bile Duct Cancer

It is information that opens a treatment option, which is generally considered meaningful. In lower-grade gliomas, IDH mutations are associated with a slower-growing tumour type compared with IDH-wild-type tumours of the same grade, and NCCN now recommends IDH inhibitor treatment in this group following surgery. In AML and bile duct cancer, the mutation identifies a subgroup for whom a targeted drug may be applicable. Whether it changes your overall outlook depends on your cancer type, stage and other molecular findings. Your oncologist is the right person to explain what the result means in your specific situation.

IDH inhibitor drugs are approved in the United States and several other countries. Access in India is subject to CDSCO approval and availability through regulated import or named-patient access programmes. The position changes as drugs progress through regulatory review, so your oncologist at CION is the best source of current information for your diagnosis. Do not purchase these drugs from unverified or online sources — drug quality and authenticity cannot be confirmed outside authorised supply channels, and the risks are real.

The mutation is identified from a sample of your tumour tissue — from a biopsy or from tissue removed during surgery. The laboratory uses techniques such as immunohistochemistry or DNA sequencing, depending on your treating centre and your oncologist's request. In most major centres, IDH testing is now standard for lower-grade brain tumours and is part of the routine molecular panel in AML. Results are usually available within one to two weeks of the sample reaching the laboratory. If testing was not done at your original diagnosis, ask whether your archived tissue sample can be used now.

No — they work through a completely different mechanism. Chemotherapy generally targets rapidly dividing cells. IDH inhibitors block the specific abnormal protein produced by the IDH mutation. They are not interchangeable with chemotherapy, and they are not used in the same situations. In lower-grade glioma, the clinical trial that supported vorasidenib's approval compared the drug against observation after surgery, not against chemotherapy directly, and NCCN guidance reflects that evidence. In AML, IDH inhibitors are used within a broader treatment sequence that may also include chemotherapy. Your oncologist will explain the rationale for your specific plan.

IDH mutations in cancer are acquired mutations — they develop in the tumour cells during a person's lifetime and are not inherited from a parent or passed to children. They are not present in normal body cells. This means the IDH mutation finding on your tumour does not carry implications for your family members' cancer risk, and family members do not need testing based on your result alone. If there is a separate concern about inherited cancer risk in your family for another reason, that is a different question to raise with your oncologist, who may refer you to a genetic counsellor.

A negative result means IDH inhibitors are not applicable for your tumour, and your treatment plan is guided by other factors — your cancer type, stage, other molecular markers, and overall fitness. In lower-grade glioma specifically, an IDH-negative result is a prompt to look more carefully at other markers, because IDH-wild-type tumours in this group often behave differently and require a different approach. Being IDH-negative does not close off treatment — it focuses your oncologist on the options that are actually indicated for your biology.